Diabetic neuropathies.
Diabetic neuropathy (DN) is a common complication of diabetes that often is associated with considerable morbidity and mortality. The epidemiology and natural history of DN is clouded with uncertainty because of confusion regarding the definition and measurement of this disorder. The recent resurgence of interest in the vascular hypothesis, oxidative stress, the neurotrophic hypothesis,and the possibility of the role of autoimmunity has opened up new avenues of investigation for therapeutic intervention. The ability to manage successfully the many different manifestations of diabetic neuropathy depends ultimately on success in uncovering the pathogenic processes underlying this disorder.
Department of Internal Medicine, The Strelitz Diabetes Institutes, Eastern Virginia Medical School, 855 West Brambleton Avenue, Norfolk, VA 23510, USA. vinikai@evms.edu
A I
AI
Vinik
Anahit
A
Mehrabyan
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D002908:Chronic Disease; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D003929:Diabetic Neuropathies / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D009431:Neural Conduction; D011379:Prognosis; D011788:Quality of Life; D018570:Risk Assessment; D012720:Severity of Illness Index; D004561:Transcutaneous Electric Nerve Stimulation / Q000379:methods; D016896:Treatment Outcome
D000700:Analgesics; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000449:Aldehyde Reductase